You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Details for Patent: 8,575,149


✉ Email this page to a colleague

« Back to Dashboard


Title:5HT2C receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Jeffrey (San Diego, CA), Smith; Brian (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Sep 14, 2012
Application Number:13/620,204
Claims:1. A method for treating a subject for a disease or disorder for which weight loss is indicated, said method comprising the steps of: administering to said subject a pharmaceutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein said subject has at least one weight related condition chosen from hypertension, cardiovascular disease, and diabetes.

3. The method of claim 1 wherein said subject has at least one weight related condition chosen from hypertension and diabetes.

4. The method of claim 1, further comprising advising said subject to increase physical activity.

5. The method of claim 1, further comprising advising said subject to reduce dietary fat content.

6. The method of claim 1, further comprising advising said subject to consume fewer calories.

7. The method of claim 1, wherein prior to said administration, the subject had a BMI of greater than 30 kg/m.sup.2.

8. The method of claim 1, wherein prior to said administration, the subject had a BMI ranging from 25 to 30 kg/m.sup.2.

9. A method of weight management in a patient in need thereof said method comprising the steps of: administering to said subject a pharmaceutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein prior to said administration, the subject had a BMI of greater than 30 kg/m.sup.2.

11. The method of claim 9, wherein prior to said administration, the subject had a BMI ranging from 25 to 30 kg/m.sup.2.

12. The method of claim 9 wherein said subject has at least one weight related condition chosen from hypertension, cardiovascular disease, and diabetes.

13. The method of claim 12 wherein said subject has at least one weight related condition chosen from hypertension and diabetes.

14. The method of claim 9, further comprising advising said subject to increase physical activity.

15. The method of claim 9, further comprising advising said subject to reduce dietary fat content.

16. The method of claim 9, further comprising advising said subject to consume fewer calories.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.